Myrobalan Therapeutics, a biotechnology company developing novel oral neurorestorative therapies to repair damage and restore neural function in high-unmet need degenerative CNS conditions, announced completion of a $24 million Series A funding. Funding was led by Co-win Ventures, with participation from new and existing investors including, Guan Zi Equity Investment (Li Shui) Partnership (Limited Partnership), 3E Bioventures Capital, and AB Magnitude Ventures Group.